These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 19015956)
1. Lactose composite carriers for respiratory delivery. Young PM; Kwok P; Adi H; Chan HK; Traini D Pharm Res; 2009 Apr; 26(4):802-10. PubMed ID: 19015956 [TBL] [Abstract][Full Text] [Related]
2. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone. Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026 [TBL] [Abstract][Full Text] [Related]
3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers. Zeng XM; MacRitchie HB; Marriott C; Martin GP Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863 [TBL] [Abstract][Full Text] [Related]
4. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate. Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688 [TBL] [Abstract][Full Text] [Related]
5. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate. Kaialy W; Ticehurst M; Nokhodchi A Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation. Traini D; Young PM; Jones M; Edge S; Price R Eur J Pharm Sci; 2006 Feb; 27(2-3):243-51. PubMed ID: 16330191 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Dry Powder Inhaler Carrier Targeted Design: A Comparative Case Study of Diverse Anomeric Compositions and Physical Properties of Lactose. Pinto JT; Zellnitz S; Guidi T; Roblegg E; Paudel A Mol Pharm; 2018 Jul; 15(7):2827-2839. PubMed ID: 29856921 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size. Du P; Du J; Smyth HD AAPS PharmSciTech; 2014 Dec; 15(6):1417-28. PubMed ID: 24962007 [TBL] [Abstract][Full Text] [Related]
9. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler. Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187 [TBL] [Abstract][Full Text] [Related]
10. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D J Pharm Sci; 2007 May; 96(5):1302-19. PubMed ID: 17455364 [TBL] [Abstract][Full Text] [Related]
11. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. Adi H; Traini D; Chan HK; Young PM J Pharm Sci; 2008 Jul; 97(7):2780-8. PubMed ID: 17894369 [TBL] [Abstract][Full Text] [Related]
12. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324 [TBL] [Abstract][Full Text] [Related]
13. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Traini D; Young PM; Thielmann F; Acharya M Drug Dev Ind Pharm; 2008 Sep; 34(9):992-1001. PubMed ID: 18800259 [TBL] [Abstract][Full Text] [Related]
14. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. Jones MD; Harris H; Hooton JC; Shur J; King GS; Mathoulin CA; Nichol K; Smith TL; Dawson ML; Ferrie AR; Price R Eur J Pharm Biopharm; 2008 Jun; 69(2):496-507. PubMed ID: 18191553 [TBL] [Abstract][Full Text] [Related]
15. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Price R; Young PM; Edge S; Staniforth JN Int J Pharm; 2002 Oct; 246(1-2):47-59. PubMed ID: 12270608 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers. Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343 [TBL] [Abstract][Full Text] [Related]
17. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler. de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246 [TBL] [Abstract][Full Text] [Related]
18. Effervescent dry powder for respiratory drug delivery. Ely L; Roa W; Finlay WH; Löbenberg R Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987 [TBL] [Abstract][Full Text] [Related]
19. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985 [TBL] [Abstract][Full Text] [Related]
20. Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers. Larhrib H; Martin GP; Prime D; Marriott C Eur J Pharm Sci; 2003 Jul; 19(4):211-21. PubMed ID: 12885385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]